Journals / Turkish Journal of Hematology / 2014 / Cilt: 31 - Sayı: 4

Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy

Uzun Süreli Transfüzyon Tedavisi Alan Hastalarda Duffy ve Kidd Genotiplendirme Transfüzyon Öncesi İncelemeleri Kolaylaştırıyor

Pages
367–373
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

If the time frame from RBC transfusion exceeds 6 weeks, Duffy phenotyping can provide accurate results

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Conventional serologic typing of red blood cell systems other than ABO and RhD can be inaccurate and difficult to interpret in patients who have recently undergone blood transfusion.
📊
Key Findings & Data:Materials and Methods:Blood samples were taken from 101 patients with haemato-oncological, chronic renal, or gastroenterological diseases and from 50 donor controls; the samples were tested for Fya and Fyb by applying serologic and genetic methods.
💡
Conclusion & Impact:If the time frame from RBC transfusion exceeds 6 weeks, Duffy phenotyping can provide accurate results
🔬Design:Research Article
📍Scope:23 samples
⚙️Variables:Domain Parameters

Abstract

Objective: Conventional serologic typing of red blood cell systems other than ABO and RhD can be inaccurate and difficult to interpret in patients who have recently undergone blood transfusion. While molecular-based assays are not used routinely, the usefulness of genotyping was investigated in order to determine patients who may benefit from this procedure. Materials and Methods:Blood samples were taken from 101 patients with haemato-oncological, chronic renal, or gastroenterological diseases and from 50 donor controls; the samples were tested for Fya and Fyb by applying serologic and genetic methods. All patients had received 3 or more units of RBCs during the last 3 months. An average of 6.1 RBC units were transfused per patient. The average length of time from transfusion until blood sampling was 24.4 days. The haemagglutination test was applied for serological analysis, and the restriction length polymorphism assay was used for genotyping.Results:In total, 33 (32.7%) patients showed positive reactions with anti-Fya or anti-Fyb while being negative genetically. Falsepositive Fya results were found in 23 samples, and false-positive Fyb in 10 specimens. During the last 3 months, significantly more RBC units were transfused to patients with discrepant results than to those with accurate phenotyping/genotyping results: median of 5 (mean ± SE: 6.85±0.69) versus median of 4 (mean: 5.71±0.51), respectively (p=0.025). The median length of time after the last transfusion was 25 days (mean: 28.72±2.23 days) in the group with accurate phenotyping/genotyping results versus a median of 14 days (mean: 15.52±1.95 days) in the group with discrepant results (p=0.001). Phenotypes and genotypes coincided in all donor samples.Conclusion:Genotyping assays for the Duffy system should be considered if the patient underwent blood transfusion less than 3 or 4 weeks before the sample collection. If the time frame from RBC transfusion exceeds 6 weeks, Duffy phenotyping can provide accurate results

Özet

Amaç: Eritrositlerin ABO ve RhD sistemleri dışındaki konvansiyonel serolojik tiplendirmesini son zamanlarda sık kan transfüzyonu yapılmış olan kişilerde yorumlamak yanlış ve zor olabilir. Bazı moleküler incelemeler henüz rutin olarak kullanılmamasına rağmen, genotiplendirmenin yararı bu işlemden fayda görecek hastaları belirlemek amacıyla incelenmiştir.Gereç ve Yöntemler:Hemato-onkoloijk, kronik böbrek hastalığı veya gastrointestinal hastalığı olan 101 hastadan ve kontrol grubu olan 50 kişiden karşılaştırmak üzere kan örnekleri alındı. Numuneler serolojik ve genetik yöntemler kullanılarak Fya ve Fyb için test edildi. Bütün hastalara son 3 ay içinde 3 ve daha fazla ünite eritrosit süspansiyonu transfüzyonu yapılmıştı. Her hasta için ortalama transfüzyon 6,1 ünite olarak hesaplandı. Transfüzyondan örneklerin alınmasına kadar geçen ortalama süre 24,4 gündü. Hemaglütinasyon testi serolojik analiz için uygulandı, ve uzunluğu kısıtlanmış polimorfizm testi genotipleme için kullanıldı. Bulgular: Genetik olarak negatif olan, toplam 33 (%32,7) hastada anti-Fya veya anti-Fyb ile pozitif reaksiyon elde edildi. Yirmi üç örnekte yanlış pozitif Fya sonucu, 10 örnekte yanlış pozitif Fyb sonucu elde edildi. Son 3 ayda fenotiplendirme/genotiplendirme sonuçları tutarsız olanlarda uyumlu olanlara göre anlamlı olarak daha fazla eritrosit süspansiyonu transfüzyon yapılmıştı: sırasıyla ortanca 5 (ortalama ± SE: 6,85±0,69) ve ortanca 4 (ortalama ± SE: 5,71±0,51) (p=0,025). Fenotiplendirme/genotiplendirmesi sonuçları uyumlu olan grupta transfüzyondan test aşamasına kadar geçen ortanca süre 25 gün (ortalama: 28,72±2,23) iken, sonuçları uyumsuz çıkan grupta bu süre ortanca 14 (ortalama: 15,52±1,95) gündü. Tüm donör örneklerinde fenotip ve genotipler tutarlıydı.Sonuç: Örnek alınmasından 3 veya 4 hafta öncesinde transfüzyon alan kişilerde Duffy sistemi için genotiplendirme yapılması uygun olabilir. Eğer eritrosit süspansiyonu transfüzyonundan sonra geçen süre 6 haftadan fazla ise, Duffy fenotiplendirmeyle uygun ve güvenilir sonuçlar sunabilir

🔖

Cite This Article

REMEİKİENE, D., UGENSKİENE, R., INCIURA, A., SAVUKAİTYTE, A., RAULİNAİTYTE, D., SKRODENİENE, E., SIMOLIUNIENE, R., JUOZAITYTE, E. (2014). Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy. Turkish Journal of Hematology, Cilt: 31 - Sayı: 4, 367–373. https://ajindex.com/articles/412561

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Wilkinson K, Harris S, Gaur P, Haile A, Armour R, Teramura G, Delaney M. Molecular typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion 2012;52:381-388
  2. Hillyer CD, Shaz BH, Winkler AM, Reid M. Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev 2008;22:117-132
  3. Ribeiro KR, Guarnieri MH, Costa DC, Costa FF, Pelegrino J Jr, Castilho L. DNA array analysis for red blood cell antigens facilitates the transfusion support with antigen-matched blood in patients with sickle cell disease. Vox Sang 2009;97:147- 152
  4. Chou ST, Westhoff CM. The role of molecular immunohematology in sickle cell disease. Transfus Apher Sci 2011;44:73-79
  5. Rozman P, Dovc T, Gassner C. Differentiation of autologous ABO, RHD, RHCE, KEL, JK and FY blood group genotypes by analysis of peripheral blood samples of patients who have recently received multiple transfusions. Transfusion 2000;40:936-942
  6. Guelsin GA, Sell AM, Castilho L, Masaki VL, Melo FC, Hashimoto MN, Higa TT, Hirle LS, Visentainer EL. Benefits of blood group genotyping in multi-transfused patients from the south of Brazil. J Clin Lab Anal 2010;24:311-316
  7. Reid ME, Rios M, Powell VI, Charles-Pierre D, Malavade V. DNA from blood samples can be used to genotype patients who have recently received a transfusion. Transfusion 2000;40:48-53
  8. Meny GM. The Duffy blood group system: a review. Immunohematology 2010;26:51-56
  9. Westhoff CM, Reid ME. Review: the Kell, Kidd, Duffy and Kidd blood group systems. Immunohematology 2004;20:37-49
  10. Schwickerath V, Kowalski M, Menitove JE. Regional registry of patient alloantibodies: first-year experience. Transfusion 2010;50:1465-1470. 11.Castilho L, Rios M, Pellegrino J Jr, Saad STO, Costa FF. Blood group genotyping facilitates transfusion of β-thalassemia patients. J Clin Lab Anal 2002;16:216-220. 12.Klapper E, Zhang Y, Figueroa P, Ness P, Stubbs J, Abumuhor I, Bailey J, Epperson L, Tauscher C, Enriques E, Hashmi G, Seul M. Toward extended phenotype matching: a new operational paradigm for the transfusion service. Transfusion 2010;50:536-546. 13.Denomme GA, Flegel WA. Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time. Transfusion 2008;48:2461- 2475
  11. Schonewille H, de Vries R, Brand A. Alloimmune response after additiona